BioCentury
ARTICLE | Clinical News

CStone to start Phase I of HDAC6 inhibitor

March 14, 2019 11:42 PM UTC

CStone said China’s National Medical Products Administration (NMPA) approved an IND for a dose-escalation Phase I trial of CS3003 to treat advanced solid tumors and relapsed or refractory multiple myeloma. The trial of the selective histone deacetylase 6 inhibitor will be conducted in China and Australia...

BCIQ Company Profiles

CStone Pharmaceuticals Co. Ltd.

BCIQ Target Profiles

Histone deacetylase 6 (HDAC6)